Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo
Figure 4
Percentage of apoptotic cells included both early- and late-stage apoptosis (AV+/PI− and AV+/PI+) was detected by FCM. The apoptosis rates of NET-1shRNA, sorafenib, combination, and untreated group were 24 ± 0.72%, 17.64 ± 0.46%, 51.34 ± 1.25%, and 6.3 ± 0.03%, respectively.